Global Vinflunine Market – Industry Trends and Forecast to 2030

Análise e dimensão do mercado de vinflunina

O cancro é a maior causa de mortalidade em todo o mundo, segundo a Organização Mundial de Saúde (OMS), sendo responsável por aproximadamente 10 milhões de mortes em 2020, ou quase uma em cada seis mortes. Cerca de 400.000 crianças são diagnosticadas com cancro todos os anos. A vinflunina é uma forma de alcalóide da vinca habitualmente utilizada para tratar o cancro. Pertence à terceira geração de alcalóides da vinca com propriedades antitumorais. Atua estimulando a paragem do ciclo celular na fase G2/M e promovendo a morte celular por apoptose. A Agência Europeia do Medicamento aprovou-o em 2009 como terapêutica de segunda linha para o carcinoma urotelial quando o tratamento com platina falhou.

A Data Bridge Market Research analisa que o mercado global de vinflunina, que foi de 8.475,23 milhões de dólares em 2022, dispararia para 15.746,14 milhões de dólares até 2030, e deverá passar por um CAGR de 11,2% durante o período de previsão. Isto indica que o valor de mercado. Espera-se que os “antineoplásicos” dominem o segmento da classe de medicamentos do mercado global de vinflunina devido à elevada procura deste tipo de medicamentos. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços, e quadro regulamentar.

Âmbito e segmentação do mercado da vinflunina

Definição de mercado

Após o insucesso de um tratamento à base de platina, a vinflunina é um alcalóide da vinca utilizado para tratar o carcinoma de células transicionais avançado ou metastático do tracto urotelial. Os efeitos antitumorais da vinflunina dependem da concentração do fármaco e do tempo de exposição. A vinflunina inibe a montagem dos microtúbulos e reduz a taxa e extensão dos eventos de crescimento dos microtúbulos em doses micromolares, resultando num efeito antimitótico. Em ratinhos, a vinflunina tem um efeito anticancerígeno contra uma vasta gama de xenoenxertos humanos, tanto em termos de sobrevivência como de inibição do crescimento tumoral. In vitro, a vinflunina é um ativador menos poderoso da resistência aos medicamentos do que outros alcalóides da vinca.

Dinâmica do mercado da vinflunina

Motoristas

• O aumento da prevalência do cancro

Estima-se que a crescente prevalência de cancro, como o cancro urotelial, carcinoma celular e outros, aumente a taxa de crescimento do mercado da vinflunina. O carcinoma urotelial da bexiga é um dos cancros mais frequentes a nível mundial, com uma incidência anual de 429.700 novos casos e uma taxa de mortalidade de 165.000. Aproximadamente 80% das pessoas afetadas têm entre 50 e 79 anos de idade As técnicas cirúrgicas são preferíveis para o cancro da bexiga não invasivo para os músculos e para as malignidades localmente invasivas e musculares invasivas.

• Proficiências em investigação e desenvolvimento

O aumento das despesas com competências em investigação e desenvolvimento, especialmente nas economias desenvolvidas e em desenvolvimento, relativas a instrumentos e dispositivos médicos, criará ainda mais oportunidades lucrativas de crescimento de mercado. As proficiências em investigação e desenvolvimento conduzidas para a integração de tecnologias avançadas em instalações de saúde estão também a reforçar a taxa de crescimento do mercado.

• Investimento crescente em instalações de saúde

O crescente foco na melhoria das condições das instalações de saúde e na melhoria das infraestruturas gerais de saúde é outro fator importante que promove o crescimento do mercado. O número crescente de parcerias e colaborações estratégicas entre os intervenientes públicos e privados relativos ao financiamento e aplicação de tecnologias novas e melhoradas está a criar ainda mais oportunidades de mercado lucrativas.  

Oportunidades

• Expansão da indústria farmacêutica

The pharmaceutical industry is experiencing growth due to various factors, including advancements in device development, increasing investments in research and development, and expanding healthcare infrastructure. This growth directly impacts the Vinflunine market.

• Government investments in healthcare infrastructure

The increase in funding by the federal government is set to drive the market growth rate. Moreover, the growth and expansion of the healthcare industry being driven by both public and private players, especially in developing economies will create lucrative market growth opportunities. Also, the high return on investments assured by the research activities will work in the favor of the market.

Restraints/Challenges

• Rising competition

The vinflunine market is highly competitive, with numerous companies offering a wide range of products. This can make it challenging for new entrants or smaller companies to gain market share and establish a strong presence.

• High cost associated with drug development and distribution

The cost of drug development and distribution is very high in the market. Healthcare systems and payers face cost pressures, and there is a growing demand for cost-effective solutions. Manufacturers need to balance the development of innovative implants with affordability to meet market demands.

This vinflunine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Vinflunine Market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In July 2021, Pierre Fabre a pharmaceutical company developed Vinflunine (brand name: Javlor). Vinflunine is a chemotherapy drug approved for the treatment of advanced or metastatic urothelial carcinoma. Pierre Fabre continues to focus on research and development to explore the potential of Vinflunine in other cancer indications and improve its therapeutic applications
• In August 2021, Mylan is a global pharmaceutical company that has been involved in the marketing and distribution of Vinflunine in various regions. Mylan has worked to expand access to Vinflunine for patients with advanced or metastatic urothelial carcinoma in different markets.

Global Vinflunine Market Scope

The VINFLUNINE market is segmented on the basis of drug class, indication, dosage forms, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Antineoplastics
• Vinca Alkaloids

Indication

• Oncology/Cancer
• Others

Dosage Forms

• Solution
• Injections
• Others

Route of Administration

• Intravenous
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Vinflunine Market Regional Analysis/Insights

The vinflunine market is analysed and market size insights and trends are provided by country, drug class, indication, dosage forms, route of administration, end-users, and distribution channel as referenced above.

The countries covered in the vinflunine market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to dominate the vinflunine market because of the strong base of healthcare facilities, strong presence of major players in the market, and rising number of research activities in this region.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in healthcare facilities, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The Vinflunine market also provides you with detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kind of products for the vinflunine market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the vinflunine Market. The data is available for the historic period 2015-2020.

Competitive Landscape and Global Vinflunine Market Share Analysis

The vinflunine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to vinflunine market.

Some of the major players operating in the vinflunine market are:

• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Fresenius Kabi AG (Germany)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Sanofi (France)
• Merck & Co., Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• Abbott (U.S.)
• Sagent Pharmaceuticals, Inc. (U.S.)
• Hikma Pharmaceuticals PLC (U.K.)
• Dr. Reddy’s Laboratories Ltd. (India)
• Eli Lilly and Company (U.S.)
• Aurobindo Pharma (India)
• Amneal Pharmaceuticals LLC. (U.S.)

SKU-53420